ADVERSE EFFECT OF MACULAR INTRARETINAL HEMORRHAGE ON THE PROGNOSIS OF SUBMACULAR HEMORRHAGE DUE TO RETINAL ARTERIAL MACROANEURYSM RUPTURE.


Journal

Retina (Philadelphia, Pa.)
ISSN: 1539-2864
Titre abrégé: Retina
Pays: United States
ID NLM: 8309919

Informations de publication

Date de publication:
May 2020
Historique:
pubmed: 17 1 2019
medline: 5 5 2021
entrez: 17 1 2019
Statut: ppublish

Résumé

To investigate the clinical course of submacular hemorrhage associated with ruptured retinal arterial macroaneurysm using swept-source optical coherence tomography. This study included 23 eyes of 23 consecutive patients diagnosed with submacular hemorrhage associated with ruptured retinal arterial macroaneurysm. Cases underwent displacement of submacular hemorrhage (vitrectomy + subretinal injection of tissue plasminogen activator + air tamponade) and were followed up for 6 months after surgery. Localization of the preoperative hemorrhage and its effect on preoperative and postoperative best-corrected visual acuity, central retinal thickness, and continuity of the ellipsoid zone were measured. Macular intraretinal hemorrhage (IRH) was observed in 17 eyes (73.9%, IRH [+] group) and was not observed in 6 eyes (26.1%, IRH [-] group). The IRH (+) group showed worse postoperative best-corrected visual acuity values compared with the IRH (-) group (0.89 ± 0.47 in logarithm of the minimal angle of resolution units, Snellen equivalent 20/155 and 0.16 ± 0.23, 20/29, respectively; P < 0.01), smaller central retinal thickness values (97.7 ± 53.5 μm, 173.0 ± 32.3 μm, respectively; P < 0.01), and a higher rate of ellipsoid zone disruption (100%, 33.3%, respectively; P < 0.01). Patients with preoperative macular IRH showed lower postoperative visual acuity and worse macular contour after submacular hemorrhage displacement compared with patients without macular IRH.

Identifiants

pubmed: 30649079
doi: 10.1097/IAE.0000000000002460
pii: 00006982-202005000-00026
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

989-997

Références

Rabb MF, Gagliano DA, Teske MP. Retinal arterial macroaneurysms. Surv Ophthalmol 1988;33:73–96.
Robertson DM. Macroaneurysms of the retinal arteries. Trans Am Acad Ophthalmol Otolaryngol 1973;77:OP55–OP67.
Abdel-Khalek MN, Richardson J. Retinal macroaneurysm: natural history and guidelines for treatment. Br J Ophthalmol 1986;70:2–11.
Lavin MJ, Marsh RJ, Peart S, Rehman A. Retinal arterial macroaneurysms: a retrospective study of 40 patients. Br J Ophthalmol 1987;71:817–825.
Tsujikawa A, Sakamoto A, Ota M, et al. Retinal structural changes associated with retinal arterial macroaneurysm examined with optical coherence tomography. Retina 2009;29:782–792.
Cleary PE, Kohner EM, Hamilton AM, Bird AC. Retinal macroaneurysms. Br J Ophthalmol 1975;59:355–361.
Palestine AG, Robertson DM, Goldstein BG. Macroaneurysms of the retinal arteries. Am J Ophthalmol 1982;93:164–171.
Yang CS, Tsai DC, Lee FL, Hsu WM. Retinal arterial macroaneurysms: risk factors of poor visual outcome. Ophthalmologica 2005;219:366–372.
Koinzer S, Heckmann J, Tode J, Roider J. Long-term, therapy-related visual outcome of 49 cases with retinal arterial macroaneurysm: a case series and literature review. Br J Ophthalmol 2015;99:1345–1353.
Zhao P, Hayashi H, Oshima K, et al. Vitrectomy for macular hemorrhage associated with retinal arterial macroaneurysm. Ophthalmology 2000;107:613–617.
Terasaki H, Miyake Y, Kondo M, Tanikawa A. Focal macular electroretinogram before and after drainage of macular subretinal hemorrhage. Am J Ophthalmol 1997;123:207–211.
Bennett SR, Folk JC, Blodi CF, Klugman M. Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol 1990;109:33–37.
Wu TT, Sheu SJ. Intravitreal tissue plasminogen activator and pneumatic displacement of submacular hemorrhage secondary to retinal artery macroaneurysm. J Ocul Pharmacol Ther 2005;21:62–67.
Humayun M, Lewis H, Flynn HW, et al. Management of submacular hemorrhage associated with retinal arterial macroaneurysms. Am J Ophthalmol 1998;126:358–361.
Bell JE, Shulman JP, Swan RJ, et al. Intravitreal versus subretinal tissue plasminogen activator injection for submacular hemorrhage. Ophthalmic Surg Lasers Imaging Retina 2017;48:26–32.
Hillenkamp J, Surguch V, Framme C, et al. Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol 2010;248:5–11.
Inoue M, Shiraga F, Shirakata Y, et al. Subretinal injection of recombinant tissue plasminogen activator for submacular hemorrhage associated with ruptured retinal arterial macroaneurysm. Graefes Arch Clin Exp Ophthalmol 2015;253:1663–1669.
van Zeeburg EJT, Cereda MG, van Meurs JC. Recombinant tissue plasminogen activator, vitrectomy, and gas for recent submacular hemorrhage displacement due to retinal macroaneurysm. Graefes Arch Clin Exp Ophthalmol 2013;251:733–740.
Sonmez K, Ozturk F, Ozcan PY. Treatment of multilevel macular hemorrhage secondary to retinal arterial macroaneurysm with submacular tissue plasminogen activator. Eur J Ophthalmol 2012;22:1026–1031.
Haupert CL, McCuen BW, Jaffe GJ, et al. Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration. Am J Ophthalmol 2001;131:208–215.
Kimura S, Morizane Y, Hosokawa M, et al. Submacular hemorrhage in polypoidal choroidal vasculopathy treated by vitrectomy and subretinal tissue plasminogen activator. Am J Ophthalmol 2015;159:683–689.
Asdourian GK, Goldberg MF, Jampol L, Rabb M. Retinal macroaneurysms. Arch Ophthalmol 1977;95:624–628.
Hirata M, Tsujikawa A, Matsumoto A, et al. Macular choroidal thickness and volume in normal subjects measured by swept-source optical coherence tomography. Invest Ophthalmol Vis Sci 2011;52:4971–4978.
Ishida T, Morohoshi K, Takeuchi Y, et al. Swept-source optical coherence tomographic findings in eyes with metastatic choroidal tumor. Am J Ophthalmol Case Rep 2017;8:44–47.
Sanders D, Peyman GA, Fishman G, et al. The toxicity of intravitreal whole blood and hemoglobin. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1975;197:255–267.
Kamei M, Tano Y. Tissue plasminogen activator-assisted vitrectomy: surgical drainage of submacular hemorrhage. Dev Ophthalmol 2009;44:82–88.
Glatt H, Machemer R. Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol 1982;94:762–773.
Toth CA, Morse LS, Hjelmeland LM, Landers MB. Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol 1991;109:723–729.
Toth CA, Benner JD, Hjelmeland LM, et al. Ultramicrosurgical removal of subretinal hemorrhage in cats. Am J Ophthalmol 1992;113:175–182.
Hochman MA, Seery CM, Zarbin MA. Pathophysiology and management of subretinal hemorrhage. Surv Ophthalmol 1997;42:195–213.
Candiello J, Cole GJ, Halfter W. Age-dependent changes in the structure, composition and biophysical properties of a human basement membrane. Matrix Biol 2010;29:402–410.
Weber IP, Yun SH, Scarcelli G, Franze K. The role of cell body density in ruminant retina mechanics assessed by atomic force and Brillouin microscopy. Phys Biol 2017;14:065006.
Ohji M, Saito Y, Hayashi A, et al. Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator. Arch Ophthalmol 1998;116:1326–1332.
Mizutani T, Yasukawa T, Ito Y, et al. Pneumatic displacement of submacular hemorrhage with or without tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol 2011;249:1153–1157.
Wu TT, Kung YH, Hong MC. Vitreous hemorrhage complicating intravitreal tissue plasminogen activator and pneumatic displacement of submacular hemorrhage. Retina 2011;31:2071–2077.
Chen CY, Hooper C, Chiu D, et al. Management of submacular hemorrhage with intravitreal injection of tissue plasminogen activator and expansile gas. Retina 2007;27:321–328.
Gopalakrishan M, Giridhar A, Bhat S, et al. Pneumatic displacement of submacular hemorrhage: safety, efficacy, and patient selection. Retina 2007;27:329–334.

Auteurs

Shinichiro Doi (S)

Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Okayama, Japan.

Shuhei Kimura (S)

Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Okayama, Japan.

Yuki Morizane (Y)

Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Okayama, Japan.

Mio M Hosokawa (MM)

Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Okayama, Japan.

Yusuke Shiode (Y)

Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Okayama, Japan.

Masayuki Hirano (M)

Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Okayama, Japan.

Shinji Toshima (S)

Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Okayama, Japan.

Kosuke Takahashi (K)

Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Okayama, Japan.

Mika Hosogi (M)

Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Okayama, Japan.

Atsushi Fujiwara (A)

Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Okayama, Japan.

Toshio Okanouchi (T)

Department of Ophthalmology, Kurashiki Medical Center, Kurashiki City, Okayama, Japan; and.

Yasushi Inoue (Y)

Department of Ophthalmology, Inoue Eye Clinic, Tamano City, Okayama, Japan.

Fumio Shiraga (F)

Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Okayama, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH